Table 2.
The Cox regression analysis for overall survival and progression free survival.
| Characteristics | Overall survival | Progression-free survival | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
| P-value | HR | 95% CI | P-value | P-value | HR | 95% CI | P-value | |
| Sex (male vs. female) | 0.577 | 0.750 | ||||||
| Age (≥ 60 vs. < 60 years) | 0.506 | 0.094 | 1.206 | 0.598–2.433 | 0.602 | |||
| Body mass index (≥ 22 kg/m2 vs. < 22 kg/m2) | 0.614 | 0.776 | ||||||
| Etiology of HCC (HBV vs. HCV vs. non-viral) | 1.000 | 0.734 | ||||||
| China liver cancer stage (IIa vs. IIIa vs. IIIb) | 0.574 | 0.196 | 0.032–1.206 | 0.079 | 0.026 | 0.440 | 0.114–1.694 | 0.232 |
| Presence of portal vein invasion (yes vs. no) | 0.214 | 0.911 | ||||||
| Presence of hepatic vein invasion (yes vs. no) | 0.264 | 0.718 | ||||||
| Baseline AFP (≥ 400 vs. < 400 ng/ml) | 0.660 | 0.325 | ||||||
| Baseline PIVKA-II (< 1000 vs. ≥ 1000 mAU/ml) | 0.997 | 0.531 | ||||||
| Intrahepatic tumor number (1-3 vs. ≥ 4) | 0.921 | 0.034 | 1.151 | 0.196–6.745 | 0.876 | |||
| Objective tumor response per RECIST v1.1 (responders vs. non-responders) | < 0.001 | 0.319 | 0.133–0.762 | 0.010 | < 0.001 | 0.432 | 0.219–0.851 | 0.015 |
| Concurrent TRIT (yes vs. no) | 0.008 | 0.286 | 0.100–0.813 | 0.019 | 0.741 | 1.121 | 0.502–2.506 | 0.781 |
HR, hazard ratio; CI, confidence interval; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, alpha-fetoprotein; PIVKA-II, protein induced by vitamin K absence-II; RECIST, response evaluation criteria in solid tumours; TRIT, transcatheter intra-arterial therapies.